MAPK Signaling
Activated MAPKs transduce the phosphorylation and activation of MAPK-activated protein kinases (MAPKAPKs), e.g. RSK, MSK, or MNK family, and MK2/3/5. There are three main MAPK families, signal-regulated kinase 1 and 2 (Erk1/2 or p44/42), the c-Jun N-terminal kinases 1-3 (JNK1-3)/ stress activated protein kinases (SAPK1A, 1B, 1C), the p38 isoforms (p38α, β, γ, and δ). ERK signaling is involved in cell division, migration and survival. p38 MAPK and JNK/SAPK pathways are activated by cellular stress. The p38 MAPK pathway regulates cell motility, transcription, and chromatin remodeling. JNK/SAPK signaling affects apoptosis and inflammation. Dysregulation of MAPK pathway results in tumorgenesis and other pathological conditions.
- A8245 Sorafenib Tosylate1 CitationTarget: Raf|VEGFRSummary: Raf kinases and tyrosine kinases inhibitor
- A5071 GDC-08791 CitationTarget: RafSummary: B-Raf inhibitor,potent and selective
- B1405 GW5074Summary: C-Raf inhibitor,potent and selective
- A8716 LY3009120Target: RafSummary: pan-RAF and RAF dimer inhibitor
- B1407 Dabrafenib (GSK2118436)3 CitationTarget: RafSummary: Inhibitor of BRAF(V600) mutants
- B1174 LGX818Target: RafSummary: RAF inhibitor,potent and selective
- A3004 Vemurafenib (PLX4032, RG7204)9 CitationTarget: RafSummary: BRAF kinase inhibitor
- A3009 Sorafenib2 CitationTarget: Raf|VEGFRSummary: Raf kinases and tyrosine kinases inhibitor
- A3016 PLX-47201 CitationTarget: RafSummary: BRAF kinase inhibitor
- A3347 Dabrafenib Mesylate (GSK-2118436)Target: RafSummary: Inhibitor of BRAF(V600) mutants